Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol

Inclusion Criteria: * (1) Patients who are currently taking or plan to take oral glucocorticoid medication for 3 months or longer and thus require treatment as per the 'Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and mineral Research (2004),' and who meet at least one of the conditions below. No restriction is imposed on the underlying disease treated with the oral glucocorticoid medication. (i) Have any existing insufficiency fracture (ii) %YAM \<80 (iii) Oral glucocorticoid daily dose \>= 5 mg prednisolone equivalent * (2) Aged between 20 and 85 years (both inclusive) at consent * (3) Patients who are able to walk without assistance * (4) Provided consent to participate in the study Exclusion Criteria: * (1) BMD (L1-4 or T-Hip) T score \< -3.5 * (2) Have 3 or more vertebral fractures between L1 and L4. * (3) Have 1 or more SQ grade 3 vertebral fractures, or 3 or more SQ grade 2 vertebral fractures. * (4) Have received a bisphosphonate preparation for 2 weeks or longer within 6 months before the start of study treatment. * (5) Have received a bisphosphonate preparation for 2 years or longer within 3 years before the start of study treatment. * (6) Have received a parathyroid hormone preparation before the start of study treatment. * (7) Have received one or more doses of an anti-RANKL (receptor activator of nuclear factor-kappa B ligand) antibody. * (8) Have received one or more doses of an anti-scl…